PT - JOURNAL ARTICLE AU - Nacev, Benjamin A. AU - Sanchez-Vega, Francisco AU - Smith, Shaleigh A. AU - Antonescu, Cristina R. AU - Rosenbaum, Evan AU - Shi, Hongyu AU - Tang, Cerise AU - Socci, Nicholas D. AU - Rana, Satshil AU - Gularte-Mérida, Rodrigo AU - Zehir, Ahmet AU - Gounder, Mrinal M. AU - Bowler, Timothy G. AU - Luthra, Anisha AU - Jadeja, Bhumika AU - Okada, Azusa AU - Strong, Jonathan A. AU - Stoller, Jake AU - Chan, Jason E. AU - Chi, Ping AU - D’Angelo, Sandra P. AU - Dickson, Mark A. AU - Kelly, Ciara M. AU - Keohan, Mary Louise AU - Movva, Sujana AU - Thornton, Katherine AU - Meyers, Paul A. AU - Wexler, Leonard H. AU - Slotkin, Emily K. AU - Glade Bender, Julia L. AU - Shukla, Neerav N. AU - Hensley, Martee L. AU - Healey, John H. AU - La Quaglia, Michael P. AU - Alektiar, Kaled M. AU - Crago, Aimee M. AU - Yoon, Sam S. AU - Untch, Brian R. AU - Chiang, Sarah AU - Agaram, Narasimhan P. AU - Hameed, Meera R. AU - Berger, Michael F. AU - Solit, David B. AU - Schultz, Nikolaus AU - Ladanyi, Marc AU - Singer, Samuel AU - Tap, William D. TI - Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets AID - 10.1101/2021.10.28.21265587 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.28.21265587 4099 - http://medrxiv.org/content/early/2021/10/30/2021.10.28.21265587.short 4100 - http://medrxiv.org/content/early/2021/10/30/2021.10.28.21265587.full AB - The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analyses analysis of 2,138 sarcomas representing 45 pathological entities. This cohort was prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations were in cell cycle control and TP53, receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations included TERT amplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varied between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.Competing Interest StatementMMG has served on advisory boards for Athenex, Ayala, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Epizyme, Karyopharm, Rain, SpringWorks Therapeutics, Tracon, and TYME Technologies; provides consulting services through Guidepoint, GLG Pharma, Third Bridge, and Flatiron Health; has received speaking honoraria from Medscape, More Health, Physicians Education Resource and touchIME; receives publishing royalties from Wolters Kluwer; holds a patent for a patient-reported outcome tool licensed through the institution; and has performed research without compensation in collaboration with Foundation Medicine. TGB is currently employed by Pfizer. PC has served on advisory boards or consulted for Deciphera, Exelixis, NingboNewBay Medical Technology, Novartis, and Zai Lab, and has received institutional research funding from Deciphera, Ningbo NewBay Medical Technology, Novartis, and Pfizer/Array. SPD has received institutional research funding from Amgen, Bristol Meyers Squibb, Deciphera, EMD Serono, Incyte, Merck, and Nektar Therapeutics, has served as a consultant or on advisory boards for Adaptimmune, Amgen, EMD Serono, GlaxoSmithKline, Immune Design, Immunocore, Incyte, Merck, and Nektar Therapeutics, and has served on data safety monitoring boards for Adaptimmune, GlaxoSmithKline, Merck, and Nektar Therapeutics. MAD has received institutional research funding from Aadi Bioscience and Eli Lilly. CMK has received research funding from Amgen, Exicure, Incyte, Kartos, Merck, Servier, and Xencor; has consulted for Exicure and Kartos; and has served on dvisory boards for Immunicum. SM has received research funding from Ascentage Pharma and Hutchison Medi Pharma. KT has served as a consultant for Epizyme and GlaxoSmithKline. PAM has served on advisory boards or consulted for Margaux Miracle Foundation, Salarius Pharmaceuticals, and Takeda, and has an immediate family member who has served on advisory boards or consulted for Boehringer Ingelheim and Genentech and received honoraria from Eastern Pulmonary Conference. JLGB has received institutional research support from Amgen, Bayer, Bristol Myers Squibb, Celgene, Cellectar Biosciences, Eisai, Ignyta, Lilly, Loxo Oncology, Merck, Novartis, and Roche; and served on data safety monitoring boards for Abbvie, Merck, and SpringWorks and on an advisory board for Bristol Myers Squibb. MLH has served on advisory boards and consulted for Eli Lilly, GlaxoSmithKline, and Thrive Bioscience, received author royalties from UpToDate, and received speaker honoraria from Research to Practice; her spouse is employed by Sanofi. JHH has consulted for Daiichi Sankyo and Stryker and is a trustee of the Musculoskeletal Transplant Foundation. AC has served on an advisory board for SpringWorks. BRU is co-inventor of intellectual property (HRAS as a biomarker of tipifarnib efficacy) that has been licensed by MSK to Kura Oncology. SC has consulted for AstraZeneca. MFB has served as a consultant for Eli Lilly and PetDx. WDT has served on advisory boards for Agios Pharmaceuticals, Bayer, Blueprint Medicines, C4 Therapeutics, Certis Oncology Solutions (in which he also owns stock), Daiichi Sankyo, Deciphera, EMD Serono, Epizyme, Innova Therapeutics, Medpacto, Mundipharma, and NanoCarrier, and has provided consulting services for Adcendo, Ayala Pharmaceuticals, Cogent Biosciences, Kowa, and Servier, holds two patents for biomarkers of CDK4 inhibitor efficacy in cancer, and is a co-founder of and owns stock in Atropos Therapeutics. DBS has consulted for BridgeBio, FORE Therapeutics, Loxo/Lilly Oncology, Pfizer, Scorpion Therapeutics, and Vividion Therapeutics. All author authors have no financial relationships to disclose.Funding StatementThis study was supported by the NCI MSK SPORE in Soft Tissue Sarcoma P50 CA217694, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, and Cycle for Survival. B.A.N. was funded by the National Cancer Institute (K08 CA245212). The Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748) supported core facility resources used in this research. P.C. is supported by the National Institute of Health/National Cancer Institute (R01 CA228216), Orphan Products Grants Program/U.S. Food and Drug Administration (R01 FD005731), Cycle for Survival, and the Geoffrey Beene Cancer Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at Memorial Sloan Kettering Cancer Center (MSK) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll clinical and genomic data described in this manuscript will be accessible online and publicly available for bulk download through the cBioPortal for Cancer Genomics.